Professional Society
American Academy of Pediatrics (Committee on Genetics)
- AAP Task Force Report on Newborn Screening
- Folic Acid for the Prevention of Neural Tube Defects
- Health Supervision for Children with Turner Syndrome
- Health Supervision for Children with Neurofibromatosis
- Health Supervision for Children with Sickle Cell Diseases and Their Families
- Health Supervision for Children with Down Syndrome
- Health Supervision for Children with Achondroplasia
- Health Supervision for Children with Fragile X Syndrome
- Health Supervision for Children with Marfan Syndrome
- Issues in Newborn Screening
- Maternal Phenylketonuria
- Newborn Screening Fact Sheets
- Newborn Screening for Congenital Hypothyriodism: Recommended Guidelines
American Academy of Pediatrics (Committee on Children with Disabilities)
American College of Medical Genetics
- ACMG Position Statement on Multiple Marker Screening in Women 35 and Older
- ASHG/ACMG Report: Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents
- Diagnostic Testing for Prader-Willi and Angelman Syndromes: Report of the ASHG/ACMG Test and Technology Transfer Committee
- Folic Acid and Pregnancy
- Fragile X Syndrome: Diagnostic and Carrier Testing
- Genetic Testing in Adoption: Joint Statement of the American Society of Human Genetics and the American College of Medical Genetics
- Position Statement on Carrier Testing for Canavan Disease
- Position Statement on Gene Patents and Accessibility of Gene Testing
- Prenatal Interphase Fluorescence In Situ Hybridization (FISH) Policy Statement
- Principles of Screening: Report of the Subcommittee on Screening of the American College of Medical Genetics Clinical Practice Committee
- Statement on Folic Acid: Fortification and Supplementation
- Statement on Genetic Testing for Cystic Fibrosis
- Statement on Guidance for Genetic Counseling in Advanced Paternal Age
- Statement on Multiple Marker Screening in Pregnant Women
- Statement on Nutritional Supplements and Piracetam for Children with Down Syndrome
- Statement on Population Screening for BRCA-1 Mutation in Ashkenazi Jewish Women
- Statement on Storage and Use of Genetic Materials
- Statement on Use of Apolipoprotein E Testing for Alzheimer Disease
- Statement on Universal Newborn Hearing Screening
American College of Obstetrics and Gynecologists (ACOG):
-
ACOG Issues Position on First-Trimester Screening Methods
Excerpt: New technologies, such as measuring nuchal translucency (NT), have allowed for earlier, noninvasive screening for chromosomal abnormalities and, when combined with serum screening in the first trimester, have comparable detection rates as standard second-trimester screening. First-trimester screening offers several potential advantages over second-trimester screening. If results are positive, it allows women to take advantage of first-trimester prenatal diagnosis by chorionic villus sampling (CVS) at 10-12 weeks or second-trimester amniocentesis ( 15 weeks).Ob-Gyns Offering Large-Scale Cystic Fibrosis Screening
Excerpt: In recent weeks, ob-gyns began to greatly expand the number of couples offered genetic screening for cystic fibrosis (CF) during preconception or prenatal care, thanks to tests made possible by genetic research. ACOG now recommends that ob-gyns make DNA screening for cystic fibrosis available to all couples seeking preconception or prenatal care - not just those with a personal or family history of carrying the CF gene, as previously recommended. Testing will be made available to all couples, whatever their risk for carrying the CF gene, through information brochures on CF given to couples seeking preconception or prenatal care.
American College of Rheumatology (Council on Research)
- Genetic and Molecular Medicine
- Genetics 101
- Ethical Issues in Carrier Screening of Genetic Disorders
- Frozen Pre-Embryos
- Genetic Counseling
- Genetic Engineering
- Genetic Testing by Employers
- GeneticDiscrimination
- Gene Therapy
- In Vitro Fertilization
- Multiplex Genetic Testing
- Patenting the Human Genome
- Insurance Companies and Genetic Information
- Genetic Testing of Children
- Pre-Embryo Splitting
- Principles of Genetic Carrier Testing
American Public Health Association
- Bioproducts Released into the Environment
- Folic Acid and the Prevention of Neural Tube Defects
- Genetics and Public Health
- Guidelines for Genetic Testing in Industry
- Maternal Serum Alpha-Fetoprotein Screening
- Preventing Birth Defects from Maternal Phenylketonuria
- Regulation of Foods Derived from Genetically Engineered Plants
- Sickle Cell
American Society of Clinical Oncology (Subcommittee on Genetic Testing for Cancer Susceptibility)
American Society of Human Genetics
- Alpha-Fetoprotein Assays
- ASHG Social Issues Committee Report on Genetics and Adoption: Points to Consider
- ASHG Position Paper on Patenting of Expressed Sequence Tags
- ASHG Human Genome Committee Report: The Human Genome Project: Implications for Human Genetics
- ASHG's Response to NIH Office of Science Policy on Draft Guidelines for Research Involving Human Pluripotent Stem Cells
- ASHG Statement on Cystic Fibrosis Screening
- ASHG Statement on Clinical Genetics and Freedom of Choice
- ASHG Statement on Cystic Fibrosis Carrier Screening
- ASHG Statement on Gene Therapy
- ASHG Statement on Genetic Testing for Breast and Ovarian Cancer Predisposition
- ASHG Statement on Use of Apolipoprotein E Testing for Alzheimer Disease
- ASHG Statement on Informed Consent for Genetic Research
- DNA Banking and DNA Analysis: Points to Consider
- Eugenics and the Misuse of Genetic Information to Restrict Reproductive Freedom
- Family History and Privacy Advisory
- Genetic Testing and Insurance
- Genetic Testing in Adoption: Joint Statement of the American Society of Human Genetics and the American College of Medical Genetics
- March 22, 2000 Response to Patent and Trademark Office
- Policy Statement for Maternal Serum Alpha-Fetoprotein Screening Programs and Quality Control for Laboratories Performing Maternal Serum and Amniotic Fluid
- Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents
- Professional Disclosure of Familial Genetic Information
- Proposed ASHG Position on Mapping/Sequencing the Human Genome
- Recent Developments in Human Behavioral Genetics: Past Accomplishments and Future Directions
- Response to National Bioethics Advisory Commission of the Ethical Issues and Policy Concerns Surrounding Research Using Human Biological Materials
- Update on MSAFP Policy Statement from the American Society of Human Genetics
Association of State and Territorial Health Officials
- Policy Positions (October 1998): 50 page document, not directly on genetics
Council of State and Territorial Epidemiologists
Institute of Medicine
National Society of Genetic Counselors
Reproductive Freedom (adopted 1987) Access to Care (adopted 1991) Nondiscrimination (adopted 1991; Rev 2002) Confidentiality of Test Results (adopted 1991; Rev 2002) Disclosure and Informed Consent (adopted 1991) Prenatal Substance Abuse(adopted 1992) Fetal Tissue Research (adopted 1992) Cystic Fibrosis (adopted 1993) (retired 2003) Genetic Screening (adopted 1994) National Health Care Reform (adopted 1994) Prenatal and Childhood Testing For Adult-onset Disorders(adopted 1995) Genetic Testing for Adult-onset Disorders(adopted 1997) DNA Sequencing Position Statement (adopted 2002) Genetic Testing and Adoption Position (adopted 2002) Standard Pedigree Symbol Position Statement (adopted 2003) Stem Cell Research (adopted 2003) Somatic Cell Nuclear Transfer (SCNT) or Cloning for Therapeutic and Reproductive Purposes (Adopted 2004) Code of Ethics: Section 1: Genetic Counselors Themselves Section 2: Genetic Counselors and Their Clients Section 3: Genetic Counselors and Their Colleagues Section 4: Genetic Counselors and Society